JamesLloydMohlerMD

PubMed

• 74 citations
  5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
  Alejandro Godoy, Elzbieta Kawinski, Yun Li, Daizo Oka, Borislav A. Alexiev
  The Prostate. 2011-07-01
• 69 citations
  Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation
  Soo-Yeon Park, Xiaofei Yu, Clement Ip, James L. Mohler, Paul N. Bogner
  Cancer Research. 2007-10-01
• 248 citations
  Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
  David V. Conti, Burcu F. Darst, Lilit C. Moss, Edward J. Saunders, Xin Sheng
  Nature Genetics. 2021-01-04

Journal Articles

• Mathematical Modeling of Intracrine Androgen Metabolism in Prostate Cancer: Methodological Aspects  
  James L Mohler, David S Watt, The Prostate
• Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backfoor pathway blockade  
  Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JM, Oncotarget, 1/1/2018
• The Men's Eating and Living (MEAL) Study (CALGB 70807 (Alliance)): Recruitment feasibility and baseline demographics of a randomized trial of diet in men on active sur...  
  Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J, BJU Int, 1/1/2018
• Proteomic analysis of charcoal-stripped fetal bovine serum reveals changes in the insulin-like growth factor signaling pathway  
  Tu C, Fiandalo MV, Pop, EA, Stocking JJ, Azabdaftari G, Li J, Wei H, Ma D, Qu J, Mohler JL, Tang L, Wu Y, J Proteome Res, 1/1/2018
• Calcium, magnesium, and whole milk intake and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP)  
  Steck S, Omofuma O, Su LJ, Maise AA, Woloszynska-Read A, Johnson CS, Zhang H, Bensen JT, Fontham ETH, Mohler JL, Arab L, Am J Clin Nutrition, 1/1/2018
• A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer  
  Mohler JL, Am J Clin Exp Urol, 1/1/2018
• Development of a patient-based model for estimating operative times for robot-assisted radical prostatectomy  
  Huben N, Hussein A, May P, Whittum M, Kraswowki C, Ahmed Y, Jing Z, Khan H, Kim H, Schwaab T, Underwood Iii W, Kauffman E, Mohler JL, Guru KA, J Endourol, 1/1/2018
• Modelling attrition and nonparticipation in a longitudinal study of prostate cancer  
  Spiers S, Oral E, Fontham ETH, Peters ES, Mohler JL, Bensen JT, Brennan CS, BMC Med Res Methodol, 1/1/2018
• Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses  
  Li Q, Deng Q, Chao, HP, Liu X, Lu Y, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puznov I, Moh..., Nat Commun, 1/1/2018
• NCCN Guidelines updates: prostate cancer and prostate cancer early detection  
  Carroll PH, Mohler JL, JNCCN (Journal of the National Comprehensive Cancer Network), 1/1/2018
• Intra- and inter-tumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators  
  Wei L, Wang J, Lampert E, Schlanger S, DePriest A, Hu Q, Gomez EC, Murakam M, Glenn S, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers H, Eur Urol, 1/1/2017
• Quality of care received and patient-reported regred in prostate cancer, analysis of a population-based prospective cohort  
  Holmes J, Bensen J, Mohler JL, Song L, Mishel M, Chen R, Cancer, 1/1/2017
• Up-regulation of follistatin-like 1 by the androgen receptor and melanoma antigen A-11 in prostate cancer  
  Su S, Parris A, Grossman G, Mohler JL, Wang Z, Wilson E, Prostate, 1/1/2017
• Saturated fat intake and prostate cancer aggressiveness: Results from the population-based North Carolina-Louisiana Prostate Cancer Project  
  Allott EH, Arab L, Su LJ, Farnan L, Fontham ETH, Mohler JL. Bensen JT, Steck SE, Prostate Cancer Prostatic Dis, 1/1/2017
• The association of diabetes and obesity with prostate cancer progression: HCaP-NC  
  Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ETH, Hendrix LH, Farnan L, Olshan AF, Bensen JT, Prostate, 1/1/2017
• Tobacco use and outcome in radical prostatectomy patients  
  Curtis A, Ondracek RP, Murekeyisoni C, Kauffman E, Mohler J, Marshall J, Cancer Med, 1/1/2017
• Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation (PLACE): intraoperative assessment of lymph node dissec...  
  Hussein AA, Hinata N, Dibaj S, May PR, Kozlowski JD, Abol-Enein H, Abaza R, Eun D, Khan MS, Mohler JL, Agarwal P, Pohar K, Sarle R, Boris R, Mane SS, Hutson A, Guru KA, BJU Int, 1/1/2017
• Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential  
  Nunez Bragayrac LA, Murekeyisoni C, Vacchio MJ, Attwood K, Mehedint DC, Mohler JL, Azabdaftari G, Xu B, Kauffman EC, Prostate, 1/1/2017
• Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)  
  Frasinyuk MS, Zhang W, Wyrebek P, Yu T, Xu X, Sviripa VM, Bondarenko SP, Xie Y, Ngo HX, Morris AJ, Mohler JL, Fiandalo MV, Watt DS, Liu C, Org Biomol Chem, 1/1/2017
• Two novel susceptibility loci for prostate cancer in men of African ancestry  
  Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John..., J Natl Cancer Inst, 1/1/2017
• Lipid degradation promotes prostate cancer cell survival  
  Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler ..., Oncotarget, 1/1/2017
• Regulators of Androgen Action Resource (RAAR): a one-stop shop for the comprehensive study of androgen receptor action  
  DePriest A, Fiandalo M, Schlanger S, Heemers F, Mohler J, Liu S, Heemers H, Database, 1/1/2016
• Antineoplastic isoflavonoids derived from intermediate ortho-quinone methides generated from mannich basses  
  Frasinyuk MS, Mrug GP, Bondarenko SP, Khilya VP, Sviripa VM, Syrotchuk OA, Zhang W, Cai W, Fiandalo MV, Mohler JL, Liu C, Watt DS, Chem Med Chem, 1/1/2016
• Carotenoid intake, adipose tissue carotenoid levels, and prostate cancer aggressiveness among African-American and European-American Men in the North Carolina-Louisian...  
  Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE, Fontham ETH, Smith GJ, Bensen JT, Mohler JL, Arab L, Prostate, 1/1/2016
• Outcomes of scheduled versus for-cause biopsy regimens for prostate cancer active surveillance  
  Al-Tartir T, Murekeyisoni C, Attwood K, Badkhshan S, Mehedint D, Safwat M, Guru K, Mohler JL, Kauffman EC, J Urol, 1/1/2016
• Join now to see all

Books/Book Chapters

• Castrate-Resistant Prostate Cancer 
  Chapter: Biology of Castration-Recurrent Prostate Cancer. 
  Page 435 - 452Azzouni F, Mohler JEditors: Kibel AS, Taneja SS.Elsevier2012
• Recent Advances in Prostate Cancer 
  Chapter: Intracrine Synthesis of Androgens by Prostate Cancer in Response to Androgen Deprivation Therapy. 
  Page 193 - 218Mohler JL, Titus MA, Godoy AS, Oka D, Nelson PSEditors: Tindall D, Scardino P.Springer Science2011
• Androgen Action in Prostate Cancer 
  Chapter: 5alpha-Reductase Isozymes in Castration-Recurrent Prostate Cancer. 
  Page 175 - 185Titus MA, Mohler JLEditors: Tindall D, Mohler JL.Springer Science2009
• Androgen Action in Prostate Cancer 
  Chapter: Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer. 
  Page 553 - 568Mohler JL, Titus MAEditors: Tindall D, Mohler JL.Springer Science2009
• Hormonal Carcinogenesis 
  Chapter: Castration-recurrent Prostate Cancer is not Androgen-Independent. 
  Page 223 - 234Mohler JEditors: Li J, Li S, Mohla S, Rochefort H, Maudelonde T.Springer2008
• Prostate Cancer: Biology, Genetics, and the New Therapeutics 
  Chapter: Racial Differences in Prostate Cancer Mortality. 
  Page 355 - 376Mohler JEditors: Simons JW, Chung LWK, Isaacs WB.The Humana Press, Inc.2008
• Best Practice and Research Clinical Endocrinology & Metabolism 
  Chapter: A Role for the Androgen Receptor in Clinically Localized and Advanced Prostate Cancer. 
  Mohler JLEditors: Labrie F.Rapid Medical Media2007
• Cancer Cell Signalling: Methods and Protocols 
  Chapter: Molecular analysis of the androgen receptor using laser capture microdissection and direct sequencing. 
  Page 287 - 302Greene SL, Stockton P, Kozyreva OG, Gaston KE, Flake GP, Mohler JLEditors: DM Terrian.Humana Press, Inc., Totowa, NJ2003
• Current Clinical Urology Series 
  Chapter: Teflon injection for incontinence after radical prostatectomy. 
  Page 89 - 100Noh C, Shusterman D, Mohler JLEditors: CC Carson.Humana Press, Inc.2002
• The 5-Minute Urology Consult 
  Chapter: Renal Vein Thrombosis. 
  Page 480 - 481Mohler JLEditors: Leonard G. Gomella.Lippincott Williams & Wilkins, Philadelphia, PA2000
• The 5-Minute Urology Consult 
  Chapter: Addison's Disease. 
  Page 188 - 189Mohler JLEditors: Leonard G. Gomella.Lippincott Williams & Wilkins, Philadelphia, PA2000
• Glenn's Urologic Surgery 
  Chapter: Inguinal lymphadenectomy for penile carcinoma. 
  Page 559 - 564Freeman JA, Mohler JLEditors: SD Graham, Jr..JP Lippincott Co., Philadelphia, PA1998
• Glenn's Urologic Surgery 
  Chapter: Penectomy for invasive squamous cell carcinoma of the penis. 
  Page 553 - 557Mohler JL, Freeman JAEditors: SD Graham, Jr..JP Lippincott Co., Philadelphia, PA1998
• Coumarin - Biology, Applications and Mode of Action 
  Chapter: The potential role of coumarins in the therapy of prostate cancer. 
  Page 241 - 253Mohler JL, Williams BT, Freeman JA, Marshall MEEditors: R. O'Kennedy and RD Thornes.John Wiley and Sons, Ltd., West Sussex, England1997
• Coumarin - Biology, Applications and Mode of Action 
  Chapter: Renal Cell Carcinoma: The background, rationale and current development of coumarin (1, 2, -benzopyrone) as a potential therapeutic agent. 
  Page 209 - 239Ebbinghaus SW, Mohler JL, Marshall MEEditors: RD Thornes and R. O'Kennedy.John Wiley and Sons, Ltd., West Sussex, England1997
• Therapy for Genitourinary Cancer 
  Chapter: Cell motility as an index of metastatic ability in prostate cancers: Results with an animal model and with human cancer cells. 
  Page 121 - 130Partin AW, Mohler JL, Coffey DSEditors: H Lepor and RK Lawson.Kluwer Academic Publishers, Boston, MA1992
• Current Therapy in Genitourinary Surgery 
  Chapter: Stage D2 prostatic adenocarcinoma. 
  Page 119 - 124Mohler JLEditors: ED Resnick and ED Kursh.BC Decker, Philadelphia, PA1992
• Prognostic Cytometry and Cytopathology of Prostate Cancer 
  Chapter: Cancer cell motility: A visual grading system for assessment of prognosis in prostatic carcinoma. 
  Page 337 - 348Mohler JL, Partin AW, Coffey DSEditors: W Gardner and DS Coffey.Elsevier, New York, NY1989
• Cancer of the Prostate. Current Practice/Future Directions 
  Chapter: Prognosis assessment in prostatic carcinoma. 
  Page 22 - 30Mohler JLEditors: AJ Wein and SB Malkowicz.CoMed, Philadelphia, PA1989
• Prognostic Cytometry and Cytopathology of Prostatic Cancer 
  Page 1 - 18Partin AW, Pitcock RV, Walsh AC, Mohler JL, Coffey DSEditors: W Gardner and DS Coffey.Elsevier, New York, NY1989
• Join now to see all

Abstracts/Posters

• Drug Development Core facilitates institutional collaboration and translational science innovation.
  Morse G, Puzanov I, Gudkov A, Difrancesco R, Jusko W, Bies R, Ernstoff M, Mohler J, Murphy T, Translational Science 2018 Meeting, Washington, DC, 1/19/2018
• High CD8+ tumor infiltrating lymphocytes at prostatectomy is associated with improved survival of prostate cancer patients.
  Yang Y, Attwood K, Versaggi C, Omilian A, Bshara W, Xu B, Kauffman E, Mohler J, Guru K, Li Q, George S, Basse P, Morrison C, Papanicolau-Sengos A, Kalinski P, Chatta GS, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Associations of genetic polymorphisms in SLCO transporters with clinical aggressiveness of prostate cancer in the North Carolina-Louisiana Prostate Cancer Project.
  Tang L, Zhu Q, Bensen J, Taylor J, Smith G, Pop E, Azabdaftari G, Mohler J, Wu Y, J Urol, 1/1/2018
• The role of polyunsaturated fatty acid metabolism on prostate cancer aggressiveness: an analysis of the North Carolina-Louisiana Prostate Cancer Project (PCaP).
  Dutta R, Rahbar E, Cui T, Seeds M, Sergeant S, Mohler J, Fontham E, Smith G, Langefeld C, Bensen J, Chilton F, J Urol, 1/1/2018
• Validation of the Decipher Biopsy Test to predict adverse pathology in men diagnosed with low and favorable intermediate risk prostate cancer.
  Lane B, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Lam L, Aranes M, du Plessis M, Davicioni E, Tosoian J, Ross A, Davis J, Mohler J, Hyndman ME, Klein ..., J Urol, 1/1/2018
• The Men's Eating and Living (MEAL) Study (CALGB 70807 (Alliance)): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer.
  Parsons J, Zarieh D, Pierce J, Mohler J, Paskett E, Hansel D, Kibel A, Hahn O, Taylor J, Grubb R, Stroup S, Small E, Van Veldhuizen P, Morris M, Marshall J, J Urol, 1/1/2018
• Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project.
  Allott EH, Arab L, Su LJ, Farnan L, Fontham ETH, Mohler JL. Bensen JT, Steck SE, American Association for Cancer Research Annual Meeting, New Orleans, LA, 1/18/2016
• Associations of polymorphisms in key androgen axis genes with clinical aggressiveness and tumor growth rate in the North Carolina-Louisiana Prostate Cancer Project (PC...
  Cheng D, Tang L, Yao S, Smith GJ, Bensen JT, Fontham ETH, Attwood KM, Pop EA, Li Y, Stocking JJ, Azabdaftari G, Ambrosone CB, Mohler JL, Third International Molecular Pathological Epidemiology (MPE) Meeting, Boston, MA, 1/12/2016
• Adrenal androgens facilitate prostate cancer cell resistance to androgen deprivation therapy.
  Fiandalo M, Stocking JJ, Pop E, Mantione K, Mohler JL, SBUR 2016 Fall Symposium, Scottsdale, AZ, 1/10/2016
• Serum free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
  Fiandalo M, Wilton J, Mantione K, Attwood K, Wu Y, Mohler JL, SBUR 2016 Fall Symposium, Scottsdale, AZ, 1/10/2016
• Is a threshold volume of disease necessary for GG3+4=7 prostate cancer to metastasize?
  Murekeyisoni C, Attwood K, Badkhshan S, Guru K, Mohler J, Kauffman E, AUA (American Urological Association) Annual Meeting, New Orleans, LA, 1/1/2015
• Fiandalo M, Wilton JH, Stocking JJ, Mongiardo KM, Li Y, Pop EA, Wilson EM, Mohler JL, 67th Northeastern American Urological Association Annual Meeting, Quebec City, Quebec, Canada, 1/1/2015
• A multicenter comparison of a 17-gene Genomic Prostate Score as a predictor of outcomes in African-American and Caucasian-American men with clinically localized prosta...
  Mohler J, Cullen J, Sesterhenn I, Srivastava S, Klein E, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis AC, Lawrence HJ, Febbo PG, 67th Northeastern American Urological Association Annual Meeting, Quebec City, Quebec, Canada, 1/1/2015
• Characterization of prostate cancer in a eunuch characterization of prostate cancer in a eunuch.
  Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Azabdaftari G, Mohler JL, SBUR 2015 Fall Symposium, Fort Lauderdale, FL, 1/1/2015
• Mutation Of The catalytic site common To 4 3alpha-oxidoreductases Impairs DHT synthesis.
  Fiandalo MV, Wilton JH, Stocking JJ, Mongiardo KM, Li Y, Pop EA, Wilson EM, Mohler JL, SBUR 2015 Fall Symposium, Fort Lauderdale, FL, 1/1/2015
• Associations between dietary antioxidant intake and prostate cancer aggressiveness among African and European American men in the North Carolina-Louisiana Prostate Can...
  Antwi S, Steck SE, Su LJ, Hebert JR, Zhang H, Fontham ETH, Bensen J, Mohler JL, Arab L, American Society of Prevention Oncology (ASPO), Arlington, VA, 1/1/2014
• Expression of de Novo lipogenic enzymes and prostate cancer progression after radical prostatectomy.
  Cheng J, Xu B, Huang H, Gao C, Chen W, Payne Ondracek R, Kasza KA, Mohler JL, Marshall JR, United States & Canadian Academy of Pathology's 103rd Annual Meeting, San Diego, CA, 1/1/2014
• Occupational risk factors for high aggressive prostate cancer in a population-based study of African Americans and European Americans.
  Su LJ, Sun W, Fontham E, Bensen J, Mohler JL, American Association for Cancer Research's International Conference on Frontiers in Cancer Prevention Research, National Harbor, MD, 1/1/2013
• Who makes the decision regarding treatment for localized prostate cancer, patient or physician? Results from a population-based study.
  Song L, Kurpad R, Udell I, Bensen J, Smith A, Nielsen M, Wallen E, Woods M, Pruthi R, Mohler J, AUA (American Urological Association) Annual Meeting, Atlanta, GA, 1/1/2012
• Cortisol serum levels are increased and induce genomic instatility in advanced prostate cancer.
  Koochekpour S, Majumdar S, Scioneaux R, Subramani D, Willard S, Azabdaftari G, Mohler J, AUA (American Urological Association) Annual Meeting, Atlanta, GA, 1/1/2012
• Serum glutamate levels are associated with primary prostate cancer aggressiveness.
  Koochekpour S, Azabdaftari G, Attwood K, Scionaux R, Majumdar S, Subramani D, Willard S, Rezaei K, Mohler J, Sartor O, Vessella R, AUA (American Urological Association) Annual Meeting, Atlanta, GA, 1/1/2012
• Flavonoid intake and prostate cancer aggressiveness among African Americans and European Americans in PCaP.
  George RR, Steck SE, Su J, Mohler JL, Fontham E, Bensen JT, Hebert JR, Zhang H, Arab L, AACR (American Association for Cancer Research) Frontiers in Basic Cancer Research, Anaheim, CA, 1/1/2012
• Diminish or eliminate androgen receptor (AR) in the immediate post-castration period.
  Wu W, Mohler J, Society for Basic Urologic Research Fall Symposium, Miami Beach, FL, 1/1/2012
• Cooperation response gene signature as a prognostic indicator for recurrent disease in prostate cancer.
  Land H, Mohler J, Collaborative Science Workshop, Rochester, NY, 1/1/2012
• 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
  Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus M, Mohler JL, 2011 AUA (American Urological Association) Annual Meeting, Washington, DC, 1/1/2011
• Join now to see all

Lectures

• NCCN Guidelines updates: new approaches to the management of prostate cancer. 
  Orlando, FL - 1/22/2018
• High adherence to a Mediterranean-style diet and the DASH eating plan is inversely associated with high aggressive prostate cancer in PCaP. 
  Baltimore, MD - 1/19/2018
• Management of prostate cancer: controversies and costs. 
  Washington, DC - 1/13/2018
• Fluorescent-androgens can be used to track androgen metabolism in prostate cancer. 
  Toronto, Canada - 1/11/2018
• Diagnosis and Treatment of Prostate Cancer: NCCN Doctrine. 
  Eilat, Israel - 1/9/2018
• Nuts and Bolts of Setting Up a Research Laboratory. 
  Palm Springs, CA - 1/8/2018
• Re-activation of the Androgen Receptor Pathway Accompanies Failure of Medical Therapy in Patients with Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Sympt... 
  Palm Springs, CA - 1/8/2018
• The Backdoor Pathway for Intracrine Androgen Metabolism: New Targets for Treatment Directed Against Androgen Receptor Action. 
  Johns Hopkins University, Baltimore, MD - 1/2/2018
• Progression-Free Survival (PSA) Endpoint. 
  Washington, DC - 1/29/2017
• Clinical Pathways for Individualized Management of Prostate Cancer: Addressing Disease Diversity with Emerging Therapies and Tailored Treatment. 
  Washington, DC - 1/8/2017
• Inhibition of Dihydrotestosterone Synthesis in Prostate Cancer by Combined Frontdoor and Backdoor Pathway Blockade. 
  Roswell Park Cancer Institute, Buffalo, NY - 1/7/2017
• Serum free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. 
  Roswell Park Cancer Institute, Buffalo, NY - 1/7/2017
• Adrenal Androgens Facilitate Prostate Cancer Cell Resistance to Androgen Deprivation Therapy. 
  Roswell Park Cancer Institute, Buffalo, NY - 1/7/2017
• Comparative Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Revealed Modified Insulin-Like Growth Factor Signaling Responsiveness. 
  Indianapolis, IN - 1/4/2017
• Evolving uses of androgen deprivation therapy (DHT) in prostate cancer management. 
  Hollywood, FL - 1/31/2016
• ADT Evolution in the NCCN Prostate Cancer Guidelines. 
  Buffalo, NY - 1/29/2016
• Intracrine androgen metabolism: new targets for treatment directed against androgen receptor action (An opportunity for better androgen deprivation therapy?). 
  New York, NY - 1/2/2016
• Update on prostate cancer management. 
  Monongahela, PA - 1/21/2015
• Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology. 
  Washington, DC - 1/20/2015
• Is primary ADT appropriate for localized prostate cancer? 
  Komatsu, Japan - 1/17/2015
• Research to address the African American prostate cancer burden. Racial differences in prostate cancer mortality: Influence of health care interaction and host and tum... 
  Washington, DC - 1/17/2015
• What are the Characteristics of an Optimal Clinical Practice Guideline? 
  Hollywood, FL - 1/14/2015
• "Value-Based Decision-Making at the Bedside", will explore how clinicians make decisions incorporating outcomes, cost, and value. 
  Hollywood, FL - 1/13/2015
• New targets for treatment of advanced prostate cancer provided by intracrine androgen metabolism. 
  Baltmore, MD - 1/5/2015
• An update on the NCCN guidelines for management of CRPC. 
  Orlando, FL - 1/19/2014
• Join now to see all

Other

• NCCN Harmonized Guidelines for the Caribbean. 
  Mohler JL, Interview, Caribbean Life eBulletin
  1/24/2018
• New Approaches to the Management of Prostate Cancer. 
  Mohler JL, The ASCO Post
  www.ascopost.com
  1/22/2018
• What If We Really Knew Where To Get The Best Cancer Care: The Prostate As Case Study. 
  Mohler JL, WBUR
  http://www.wbur.org/commonhealth/2017/01/30/prostate-cancer-quality-measures
  1/30/2017
• Aspirin and reduced risk of dying from prostate cancer. 
  Mohler JL, Medscape.com
  1/5/2016
• NEJM article exposes overuse of radiation therapy services when urologists profit in self-referral practices. 
  Mohler JL, American Society for Radiation Oncology (ASTRO) Webcast Press Conference
  Washington, DC - 1/24/2013
• Congressional testimony to the Senate Committee on Foreign Relations. 
  Mohler JL
  http://foreign.senate.gov/hearings/hearing/?id=4cceed6b-5056-a032-5229-6a73904c7998
  Washington, DC - 1/29/2010
• Congressional testimony to the House Committee on Oversight and Government Reform. 
  Mohler JL
  Washington, DC - 1/1/2010
• NCCN Prostate Cancer Guidelines Update 2010. 
  Mohler JL, NCCN/QuantiaMD Prostate Cancer Guidelines
  https://secure.quantiamd.com/player/pinpcfk?cid=53
  1/1/2010
• Androgen-independent prostate cancer is not androgen independent. 
  Mohler JL, American Urological Association
  Chicago, IL - 1/28/2009
• Prostate Cancer 
  Mohler JL, National Comprehensive Cancer Network Oncology Case Management Program Webinar
  1/18/2009
• Prostate Cancer Awareness. 
  Mohler JL, WUFO Radio Show
  Buffalo, NY - 1/25/2004
• "Racial differences in and early detection strategies for prostate cancer." 
  Mohler JL, Health Talk, WYSL-1040
  Rochester, NY - 1/18/2004
• Prostate Cancer Highlights 
  Mohler JL, Annual Meeting of the American Urological Association
  Las Vegas, NV - 1/25/1995
• The motility of cells from renal cell carcinomas. 
  Mohler JL, Video, Annual Meeting of the American Urological Association
  Boston, MA - 1/6/1988
• Join now to see all